Next Article in Journal
The Effect of Physicochemical Modification on the Function of Antibodies Induced by Anti-Nicotine Vaccine in Mice
Previous Article in Journal
Oncolytic Alphaviruses in Cancer Immunotherapy
Article

Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax

1
The Jenner Institute, Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), University of Oxford, Oxford OX3 7BN, UK
2
Allergy Therapeutics (UK) Ltd. Dominion Way, Worthing BN14 8SA, UK
3
Immunology, RIA, Inselspital, University of Bern, Bern 3012, Switzerland
4
Bencard Allergie, Messerschmittstraße 4, München 80992, Germany
*
Authors to whom correspondence should be addressed.
Current Address: The Henry Wellcome Building for Molecular Physiology, Roosevelt Drive, Oxford OX3 7BN, UK.
Academic Editor: C.A.H.H. (Toos) Daemen
Vaccines 2017, 5(2), 10; https://doi.org/10.3390/vaccines5020010
Received: 24 February 2017 / Revised: 18 April 2017 / Accepted: 21 April 2017 / Published: 2 May 2017
Vaccination is the most effective prophylactic tool against infectious diseases. Despite continued efforts to control malaria, the disease still generally represents a significant unmet medical need. Microcrystalline tyrosine (MCT) is a well described depot used in licensed allergy immunotherapy products and in clinical development. However, its proof of concept in prophylactic vaccines has only recently been explored. MCT has never been used in combination with virus-like particles (VLPs), which are considered to be one of the most potent inducers of cellular and humoral immune responses in mice and humans. In the current study we assessed the potential of MCT to serve as an adjuvant in the development of a vaccine against malaria either alone or combined with VLP using Plasmodium vivax thrombospondin-related adhesive protein (TRAP) as a target antigen. We chemically coupled PvTRAP to VLPs derived from the cucumber mosaic virus fused to a universal T-cell epitope of the tetanus toxin (CMVtt), formulated with MCT and compared the induced immune responses to PvTRAP formulated in PBS or Alum. The protective capacity of the various formulations was assessed using Plasmodium berghei expressing PvTRAP. All vaccine formulations using adjuvants and/or VLP increased humoral immunogenicity for PvTRAP compared to the antigen alone. The most proficient responder was the group of mice immunized with the vaccine formulated with PvTRAP-VLP + MCT. The VLP-based vaccine formulated in MCT also induced the strongest T cell response and conferred best protection against challenge with recombinant Plasmodium berghei. Thus, the combination of VLP with MCT may take advantage of the properties of each component and appears to be an alternative biodegradable depot adjuvant for development of novel prophylactic vaccines. View Full-Text
Keywords: vaccine; adjuvants; Plasmodium vivax; malaria; virus like particle (VLP); microcrystalline tyrosine (MCT) vaccine; adjuvants; Plasmodium vivax; malaria; virus like particle (VLP); microcrystalline tyrosine (MCT)
Show Figures

Figure 1

MDPI and ACS Style

Cabral-Miranda, G.; Heath, M.D.; Mohsen, M.O.; Gomes, A.C.; Engeroff, P.; Flaxman, A.; Leoratti, F.M.S.; El-Turabi, A.; Reyes-Sandoval, A.; Skinner, M.A.; Kramer, M.F.; Bachmann, M.F. Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax. Vaccines 2017, 5, 10. https://doi.org/10.3390/vaccines5020010

AMA Style

Cabral-Miranda G, Heath MD, Mohsen MO, Gomes AC, Engeroff P, Flaxman A, Leoratti FMS, El-Turabi A, Reyes-Sandoval A, Skinner MA, Kramer MF, Bachmann MF. Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax. Vaccines. 2017; 5(2):10. https://doi.org/10.3390/vaccines5020010

Chicago/Turabian Style

Cabral-Miranda, Gustavo, Matthew D. Heath, Mona O. Mohsen, Ariane C. Gomes, Paul Engeroff, Amy Flaxman, Fabiana M.S. Leoratti, Aadil El-Turabi, Arturo Reyes-Sandoval, Murray A. Skinner, Matthias F. Kramer, and Martin F. Bachmann. 2017. "Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax" Vaccines 5, no. 2: 10. https://doi.org/10.3390/vaccines5020010

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop